Eckert & Ziegler Reports Earnings and Sales Growth in 2025

In the first nine months of 2025, Eckert & Ziegler SE demonstrated robust financial performance with a 4% increase in sales, reaching €224.1 million compared to the previous year. The earnings before interest and taxes (EBIT) before special items rose by 9% to €50.8 million. Net income for the period surged by 28% to €29.9 million, indicating strong operational performance.

Within the Medical segment, sales grew by 15% to €119.7 million. This growth was driven by pharmaceuticals, radioisotope sales, and contract manufacturing and development services. Conversely, the Isotope Products segment faced a decline, with sales dropping by 6% due to shifts toward lower-margin products.

The company maintains its forecast for the fiscal year 2025, projecting sales of approximately €320 million and an adjusted EBIT of around €78 million. These results underline Eckert & Ziegler’s resilience and strategic focus on the Medical segment.